6:12 PM
 | 
Dec 10, 2012
 |  BC Extra  |  Company News

Biogen Idec, Isis in third deal

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) granted Biogen Idec Inc. (NASDAQ:BIIB) an exclusive, worldwide option to develop and commercialize antisense candidates against three undisclosed targets to treat neurological or neuromuscular disorders. Isis, which is responsible for discovery and development through the first Phase II...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >